Gómez A, Martos F, Bellido I, Marquez E, Garcia A J, Pavia J, Sanchez de la Cuesta F
Department of Pharmacology, Faculty of Medicine, Málaga University, Spain.
Biochem Pharmacol. 1992 Jun 9;43(11):2413-9. doi: 10.1016/0006-2952(92)90321-9.
Muscarinic receptor subtypes in human and rat colon smooth muscle homogenates were characterized with [3H]N-methylscopolamine ([3H]NMS) by ligand binding studies. [3H]NMS saturation experiments show the existence of a homogeneous population of non-interacting binding sites with similar affinity (KD values of 1.38 +/- 0.20 nM in human colon smooth muscle and 1.48 +/- 0.47 nM in rat colon smooth muscle) and with Hill slopes close to unity in both samples of tissue. However, a significant (P less than 0.01) increase in muscarinic receptor density (Bmax) is found in human colon (29.9 +/- 2.9 fmol/mg protein) compared with rat colon (17.2 +/- 1.5 fmol/mg protein). Inhibition of [3H]NMS binding by non-labelled compounds shows the following order in human colon: atropine greater than AF-DX 116 greater than pirenzepine. Whereas in rat colon the rank order obtained is atropine greater than pirenzepine greater than AF-DX 116. Atropine and pirenzepine bind to a homogeneous population of binding sites, although pirenzepine shows higher affinity to bind to the sites present in rat colon (Ki = 1.08 +/- 0.08 microM) than those in human colon (Ki = 1.74 +/- 0.02 microM) (P less than 0.05). Similarly, IC50 values obtained in AF-DX 116 competition experiments were significantly different (P less than 0.01) in human colon (IC50 = 1.69 +/- 0.37 microM) than in rat colon (IC50 = 3.78 +/- 0.75 microM). Unlike atropine and pirenzepine, the inhibition of [3H]NMS binding by AF-DX 116 did not yield a simple mass-action binding curve (nH less than 1, P less than 0.01) suggesting the presence of more than one subtype of muscarinic receptor in both species. Computer analysis of these curves with a two binding site model suggests the presence of two populations of receptor. The apparent Ki1 value for the high affinity binding site is 0.49 +/- 0.07 microM for human colon smooth muscle and 0.33 +/- 0.05 microM for rat colon smooth muscle. The apparent Ki2 for the low affinity binding site is 8.01 +/- 1.0 microM for human samples and 6.07 +/- 1.1 microM for rat samples. These values are close enough to suggest that the first subtype of muscarinic receptor may be considered cardiac (M2) and the second subtype glandular (M3). The relative densities of the receptor subtypes are significantly different for both species. Human colon samples show the major densities of subtype M2, 22.62 +/- 1.11 fmol/mg protein, this represents 75.66 +/- 3.73% of the total receptors.(ABSTRACT TRUNCATED AT 400 WORDS)
通过配体结合研究,用[³H]N-甲基东莨菪碱([³H]NMS)对人和大鼠结肠平滑肌匀浆中的毒蕈碱受体亚型进行了表征。[³H]NMS饱和实验表明存在一群亲和力相似的非相互作用结合位点(人结肠平滑肌中KD值为1.38±0.20 nM,大鼠结肠平滑肌中为1.48±0.47 nM),且两个组织样本的希尔斜率均接近1。然而,与大鼠结肠(17.2±1.5 fmol/mg蛋白)相比,人结肠中的毒蕈碱受体密度(Bmax)显著增加(P<0.01)(29.9±2.9 fmol/mg蛋白)。非标记化合物对[³H]NMS结合的抑制在人结肠中呈现以下顺序:阿托品>AF-DX 116>哌仑西平。而在大鼠结肠中得到的顺序是阿托品>哌仑西平>AF-DX 116。阿托品和哌仑西平与一群同质的结合位点结合,尽管哌仑西平对大鼠结肠中存在的位点(Ki = 1.08±0.08 μM)的结合亲和力高于人结肠中的位点(Ki = 1.74±0.02 μM)(P<0.05)。同样,在AF-DX 116竞争实验中获得的IC50值在人结肠(IC50 = 1.69±0.37 μM)和大鼠结肠(IC50 = 3.78±0.75 μM)中也有显著差异(P<0.01)。与阿托品和哌仑西平不同,AF-DX 116对[³H]NMS结合的抑制未产生简单的质量作用结合曲线(nH<1,P<0.01),这表明两种物种中均存在不止一种毒蕈碱受体亚型。用双结合位点模型对这些曲线进行计算机分析表明存在两种受体群体。人结肠平滑肌高亲和力结合位点的表观Ki1值为0.49±0.07 μM,大鼠结肠平滑肌为0.33±0.05 μM。人样本低亲和力结合位点的表观Ki2为8.01±1.0 μM,大鼠样本为6.07±1.1 μM。这些值足够接近,表明第一种毒蕈碱受体亚型可能被认为是心脏型(M2),第二种是腺体型(M3)。两种物种中受体亚型的相对密度有显著差异。人结肠样本显示亚型M2的主要密度为22.62±1.11 fmol/mg蛋白,占总受体的75.66±3.73%。(摘要截断于400字)